AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets

PLoS Genetics

Volumn 4, Issue 11, 2008, Pages

  Gardini, Alessandro ^a   Cesaroni, Matteo ^a   Luzi, Lucilla ^b   Okumura, Akiko J ^c   Biggs, Joseph R ^c   Minardi, Simone P ^b,d   Venturini, Elisa ^d   Zhang, Dong Er ^c   Pelicci, Pier Giuseppe ^a,e   Alcalay, Myriam ^a,d,e  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d IFOM IEO Campus   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYLEOID LEUKEMIA 1 PROTEIN; ACUTE MYLEOID LEUKIEMIA 1/ETO ONCOPROTEIN; HEB PROTEIN; HYBRID PROTEIN; ONCOPROTEIN; PROTEIN; UNCLASSIFIED DRUG; AML1 ETO FUSION PROTEIN, HUMAN; AML1-ETO FUSION PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; RUNX1 PROTEIN, HUMAN; TCF12 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RUNX1;

ANIMAL CELL; ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSCRIPTION REGULATION; WILD TYPE; ANIMAL; CELL STRAIN U937; CHROMOSOME 19; GENETIC TRANSCRIPTION; GENETICS; HELA CELL; METABOLISM; PROMOTER REGION; TUMOR CELL LINE;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BINDING SITES; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 19; CORE BINDING FACTOR ALPHA 2 SUBUNIT; HELA CELLS; HUMANS; MICE; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; U937 CELLS;

EID: 57149101138     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1000275     Document Type: Article

References (39)

1. Alcalay M, Orleth A, Sebastiani C, Meani N, Chiaradonna F, et al. (2001) Common themes in the pathogenesis of acute myeloid leukemia. Oncogene 20: 5680-5694.
2. Cameron ER, Neil JC (2004) The Runx genes: lineage-specific oncogenes and tumor suppressors. Oncogene 23: 4308-4314.
3. de Bruijn MF, Speck NA (2004) Core-binding factors in hematopoiesis and immune function. Oncogene 23: 4238-4248.
4. Davis JN, McGhee L, Meyers S (2003) The ETO (MTG8) gene family. Gene 303: 1-10.
5. Nimer SD, Moore MA (2004) Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells. Oncogene 23: 4249-4254.
6. Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, et al. (1997) Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 15: 303-306.
7. Okuda T, Cai Z, Yang S, Lenny N, Lyu CJ, et al. (1998) Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 91: 3134-3143.
8. Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, et al. (2001) AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A 98: 10398-10403.
9. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, et al. (2002) Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1: 63-74.
10. Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, et al. (2006) A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 12: 945-949.
11. Meyers S, Downing JR, Hiebert SW (1993) Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 13: 6336-6345.
12. Okumura AJ, Peterson LF, Okumura F, Boyapati A, Zhang DE (2008) t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. Blood 112: 1392-1401.
13. Meyers S, Lenny N, Hiebert SW (1995) The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 15: 1974-1982.
14. Uchida H, Zhang J, Nimer SD (1997) AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol 158: 2251-2258.
15. Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, et al. (1995) The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 11: 2667-2674.
16. Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD (1996) The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci U S A 93: 14059-14064.
17. Rhoades KL, Hetherington CJ, Rowley JD, Hiebert SW, Nucifora G, et al. (1996) Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci U S A 93: 11895-11900.
18. Shimada H, Ichikawa H, Nakamura S, Katsu R, Iwasa M, et al. (2000) Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF. Blood 96: 655-663.
19. Shimizu K, Kitabayashi I, Kamada N, Abe T, Maseki N, et al. (2000) AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon. Blood 96: 288-296.
20. Mulloy JC, Jankovic V, Wunderlich M, Delwel R, Cammenga J, et al. (2005) AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci U S A 102: 4016-4021.
21. Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG (2004) E protein silencing by the leukemogenic AML1-ETO fusion protein. Science 305: 1286-1289.
22. Hunger SP, Galili N, Carroll AJ, Crist WM, Link MP, et al. (1991) The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. Blood 77: 687-693.
23. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M (2004) TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 5: 587-596.
24. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, et al. (2003) Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 112: 1751-1761.
25. Matozaki S, Nakagawa T, Kawaguchi R, Aozaki R, Tsutsumi M, et al. (1995) Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t(8;21) who acquired monosomy 17 during disease progression. Br J Haematol 89: 805-811.
26. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B (2001) Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 15: 2069-2082.
27. Meani N, Minardi S, Licciulli S, Gelmetti V, Coco FL, et al. (2005) Molecular signature of retinoic acid treatment in acute promyelocytic leukemia. Oncogene 24: 3358-3368.
28. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, et al. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628.
29. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30.
30. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, et al. (2000) Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287: 1804-1808.
31. Peterson LF, Yan M, Zhang DE (2007) The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood 109: 4392-4398.
32. Murre C (2005) Helix-loop-helix proteins and lymphocyte development. Nat Immunol 6: 1079-1086.
33. Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, et al. (2001) Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol 21: 5577-5590.
34. Kim TH, Barrera LO, Zheng M, Qu C, Singer MA, et al. (2005) A highresolution map of active promoters in the human genome. Nature 436: 876-880.
35. Finocchiaro G, Parise P, Minardi SP, Alcalay M, Muller H (2004) GenePicker: replicate analysis of Affymetrix gene expression microarrays. Bioinformatics 20: 3670-3672.
36. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
37. Minucci S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, et al. (2002) PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 100: 2989-2995.
38. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, et al. (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76.
39. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, et al. (1998) Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18: 7185-7191.